S Suvakov1,2, C Richards3, V Nikolic4, T Simic2,5, K McGrath3, A Krasnodembskaya6, L McClements7. 1. Department of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. 2. Institute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 3. School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW, Australia. 4. Department of Pharmacology and Toxicology, Medical Faculty, University of Nis, Nis, Serbia. 5. Serbian Academy of Sciences and Arts, Belgrade, Serbia. 6. The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK. 7. School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW, Australia. Lana.McClements@uts.edu.au.
Abstract
PURPOSE OF REVIEW: Preeclampsia is a dangerous pregnancy condition affecting both the mother and offspring. It is a multifactorial disease with poorly understood pathogenesis, lacking effective treatments. Maternal immune response, inflammation and oxidative stress leading to endothelial dysfunction are the most prominent pathogenic processes implicated in preeclampsia development. Here, we give a detailed overview of the therapeutic applications and mechanisms of mesenchymal stem/stromal cells (MSCs) as a potential new treatment for preeclampsia. RECENT FINDINGS: MSCs have gained growing attention due to low immunogenicity, easy cultivation and expansion in vitro. Accumulating evidence now suggests that MSCs act primarily through their secretomes facilitating paracrine signalling that leads to potent immunomodulatory, pro-angiogenic and regenerative therapeutic effects. MSCs have been studied in different animal models of preeclampsia demonstrating promising result, which support further investigations into the therapeutic effects and mechanisms of MSC-based therapies in preeclampsia, steering these therapies into clinical trials.
PURPOSE OF REVIEW: Preeclampsia is a dangerous pregnancy condition affecting both the mother and offspring. It is a multifactorial disease with poorly understood pathogenesis, lacking effective treatments. Maternal immune response, inflammation and oxidative stress leading to endothelial dysfunction are the most prominent pathogenic processes implicated in preeclampsia development. Here, we give a detailed overview of the therapeutic applications and mechanisms of mesenchymal stem/stromal cells (MSCs) as a potential new treatment for preeclampsia. RECENT FINDINGS: MSCs have gained growing attention due to low immunogenicity, easy cultivation and expansion in vitro. Accumulating evidence now suggests that MSCs act primarily through their secretomes facilitating paracrine signalling that leads to potent immunomodulatory, pro-angiogenic and regenerative therapeutic effects. MSCs have been studied in different animal models of preeclampsia demonstrating promising result, which support further investigations into the therapeutic effects and mechanisms of MSC-based therapies in preeclampsia, steering these therapies into clinical trials.
Authors: A L Tranquilli; G Dekker; L Magee; J Roberts; B M Sibai; W Steyn; G G Zeeman; M A Brown Journal: Pregnancy Hypertens Date: 2014-02-15 Impact factor: 2.899
Authors: Joshua M Hare; Jay H Traverse; Timothy D Henry; Nabil Dib; Robert K Strumpf; Steven P Schulman; Gary Gerstenblith; Anthony N DeMaria; Ali E Denktas; Roger S Gammon; James B Hermiller; Mark A Reisman; Gary L Schaer; Warren Sherman Journal: J Am Coll Cardiol Date: 2009-12-08 Impact factor: 24.094
Authors: Ben W J Mol; Claire T Roberts; Shakila Thangaratinam; Laura A Magee; Christianne J M de Groot; G Justus Hofmeyr Journal: Lancet Date: 2015-09-02 Impact factor: 79.321
Authors: Charlotte Gustafsson; Jenny Mjösberg; Andreas Matussek; Robert Geffers; Leif Matthiesen; Göran Berg; Surendra Sharma; Jan Buer; Jan Ernerudh Journal: PLoS One Date: 2008-04-30 Impact factor: 3.240
Authors: Elizabeth S Taglauer; Angeles Fernandez-Gonzalez; Gareth R Willis; Monica Reis; Vincent Yeung; Xianlan Liu; Lawrence S Prince; S Alex Mitsialis; Stella Kourembanas Journal: Am J Respir Cell Mol Biol Date: 2022-01 Impact factor: 7.748
Authors: Elizabeth S Taglauer; Angeles Fernandez-Gonzalez; Gareth R Willis; Monica Reis; Vincent Yeung; Xianlan Liu; S Alex Mitsialis; Stella Kourembanas Journal: Biol Reprod Date: 2021-02-11 Impact factor: 4.285
Authors: Jatin Machhi; Farah Shahjin; Srijanee Das; Milankumar Patel; Mai Mohamed Abdelmoaty; Jacob D Cohen; Preet Amol Singh; Ashish Baldi; Neha Bajwa; Raj Kumar; Lalit K Vora; Tapan A Patel; Maxim D Oleynikov; Dhruvkumar Soni; Pravin Yeapuri; Insiya Mukadam; Rajashree Chakraborty; Caroline G Saksena; Jonathan Herskovitz; Mahmudul Hasan; David Oupicky; Suvarthi Das; Ryan F Donnelly; Kenneth S Hettie; Linda Chang; Howard E Gendelman; Bhavesh D Kevadiya Journal: Adv Drug Deliv Rev Date: 2021-01-09 Impact factor: 17.873
Authors: Naomi Todd; Ross McNally; Abdelrahim Alqudah; Djurdja Jerotic; Sonja Suvakov; Danilo Obradovic; Denise Hoch; Jose R Hombrebueno; Guillermo Lopez Campos; Chris J Watson; Miroslava Gojnic-Dugalic; Tatjana P Simic; Anna Krasnodembskaya; Gernot Desoye; Kelly-Ann Eastwood; Alyson J Hunter; Valerie A Holmes; David R McCance; Ian S Young; David J Grieve; Louise C Kenny; Vesna D Garovic; Tracy Robson; Lana McClements Journal: J Clin Endocrinol Metab Date: 2021-01-01 Impact factor: 5.958
Authors: Ingrid Aneman; Dillan Pienaar; Sonja Suvakov; Tatjana P Simic; Vesna D Garovic; Lana McClements Journal: Front Immunol Date: 2020-08-18 Impact factor: 7.561
Authors: Sean T Ryan; Elham Hosseini-Beheshti; Dinara Afrose; Xianting Ding; Binbin Xia; Georges E Grau; Christopher B Little; Lana McClements; Jiao Jiao Li Journal: Int J Mol Sci Date: 2021-03-16 Impact factor: 5.923